3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
2
Phase EARLY_PHASE1
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Other solid neoplasm
2
Gastrointestinal
1
Conditions
Mesothelioma, Malignant
2
Severe combined immunodeficiency with sensitivity to ionizing radiation
1
Interventions
Cisplatin
42
Pemetrexed
31
Carboplatin
28
Nivolumab
21
pembrolizumab
19
Gemcitabine
19
atezolizumab
13
Etoposide
13
Injections
12
Ipilimumab
11
Cyclophosphamide
11
Radiotherapy
10
Oxaliplatin
10
Filgrastim
10
Docetaxel
10
Bevacizumab
10
tislelizumab
9
Vincristine
9
Specimen Handling
9
durvalumab
8
Paclitaxel
8
Capecitabine
8
tremelimumab
7
toripalimab
7
lenvatinib
7
Everolimus
7
spartalizumab
6
olaparib
6
niraparib
6
Vinorelbine
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
amatuximab
×
Other solid neoplasm
×
Clear all
NCT00738582
2022-09-22
Amatuximab
Morphotek
Phase 2
Completed
89 enrolled
12 charts
NCT02357147
2020-03-17
ARTEMIS
Morphotek
Phase 2
Terminated
124 enrolled
10 charts